

Male Breast Cancer

Ian Fentiman

Male Breast Cancer

 Springer

Ian Fentiman
Research Oncology
Guy's Hospital
London, United Kingdom

ISBN 978-3-319-04668-6 ISBN 978-3-319-04669-3 (eBook)
DOI 10.1007/978-3-319-04669-3

Library of Congress Control Number: 2017934342

© Springer International Publishing Switzerland 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

This book is an attempt to bring together the available data concerning male breast cancer. What emerges is a piecemeal collection of reports all of which are unsullied by randomised controlled trials. These gaps in our knowledge about a rare disease will, I hope, act as a stimulant to collaborative efforts to improve the patient journey and the long-term outcome for men with breast cancer. I am most grateful to the following colleagues who kindly pointed out my more major errors and omissions:

Professor Nigel Bundred
Professor Michael Douek
Professor Dame Lesley Fallowfield
Professor Andy Hanby
Dr Mark Harries
Professor Lars Holmberg
Professor Anthony Howell
Professor Arnie Purushotham
Professor Ellen Solomon
Professor Valerie Spiers
Professor Anthony Swerdlow
Dr Robin Wilson

London, UK
November 2016

Ian Fentiman

Contents

1 The Problem	1
Introduction.....	1
Male Health Behaviour	2
Delay in MBC	3
Age and Stage at Presentation.....	4
Incidence	5
Male Breast Anatomy	5
Model Systems.....	6
Collaboration.....	7
References.....	7
2 Clinical Features and Diagnosis	11
Presentation.....	11
Clinical Evaluation.....	12
Imaging	14
Breast MRI.....	18
¹⁸ F-FDG PET/CT	19
Fine Needle Aspiration Cytology (FNAC).....	20
Core Biopsy	21
References.....	22
3 Risk Factors	25
Age.....	25
Ethnicity.....	26
Sociodemographic Status.....	28
Klinefelter's Syndrome	28
Gynaecomastia.....	29
Testicular Malfunction	32
Transsexuality	35
Prostate Cancer	36

Modifiable Factors	36
Smoking	36
Alcohol.....	37
Weight	37
Diet.....	38
Occupation	38
Ionising Radiation.....	40
Electromagnetic Fields EMF	42
HIV	43
References.....	44
4 Genetics.....	51
Aneuploidy.....	52
<i>BRCA1/2</i>	52
Other Susceptibility Genes	53
<i>PALB2</i>	53
<i>RAD51C</i>	54
EMSY	55
<i>BCoRL1</i>	55
<i>PIK3CA</i>	55
Ataxia-Telangectasia Mutated (ATM)	55
Androgen Receptor Gene.....	56
<i>CYP17</i>	56
<i>CHEK-2</i>	57
Genetic Testing	58
Histopathology.....	59
References.....	60
5 Histopathology.....	63
Introduction.....	63
Intracystic Papillary Carcinoma.....	65
Benign Papilloma.....	65
Intracystic Papillary Carcinoma (DCIS)	66
Invasive Papillary Carcinoma	67
Invasive Lobular Carcinoma	69
Pleomorphic Invasive Lobular Carcinoma.....	70
Secretory Cancer.....	71
Adenoid Cystic Carcinoma	73
Mucinous Carcinoma.....	74
Sarcoma.....	75
Phyllodes Tumour	75
Angiosarcoma	76
Liposarcoma.....	77
Fibrosarcoma.....	77
Malignant Fibrous Histiocytoma (MFH).....	78

Dermatofibrosarcoma Protuberans.....	78
Osteogenic Sarcoma.....	79
References.....	79
6 Molecular Profile.....	87
Introduction.....	87
Estrogen and Progesterone Receptors.....	87
Androgen Receptor.....	88
Ki67/MIB-1.....	90
Bcl2.....	91
Molecular Subtypes.....	91
Cell Cycle Proteins.....	93
Oncotype DX™.....	94
References.....	94
7 Psychosocial.....	97
Introduction.....	97
Risk.....	98
Post-diagnosis Problems.....	99
References.....	103
8 Surgery.....	105
Mastectomy and Breast Conserving Surgery.....	106
Sentinel Node Biopsy.....	108
Reconstructive Surgery.....	109
Ductal Carcinoma in Situ.....	110
Presenting Symptoms.....	110
Histology.....	111
Surgery.....	111
Recommendations.....	112
References.....	113
9 Adjuvant Therapy.....	115
Adjuvant Endocrine Therapy.....	115
Compliance.....	118
Aromatase Inhibitors (AIs).....	119
Adjuvant Chemotherapy.....	120
Radiotherapy.....	122
Problems.....	126
References.....	126
10 Treatment of Advanced Disease.....	129
Introduction.....	129
History.....	130
Adrenalectomy.....	131
Hypophysectomy.....	131

Estrogens.....	132
Antiandrogens.....	133
Progestins.....	133
Androgens.....	134
Tamoxifen.....	135
Aromatase Inhibitors.....	135
Fulvestrant.....	137
GnRH Analogues.....	138
Chemotherapy.....	139
References.....	141
11 Prognosis.....	145
Males Versus Females.....	145
Age.....	149
Marital Status.....	150
Ethnicity.....	151
Molecular Profile.....	153
Triple Negative.....	156
HER2.....	156
Oncotype DX TM	157
<i>BRCA2</i> Mutations.....	157
Hypoxia.....	158
GATA-3.....	159
Plasminogen Activator.....	160
Hippo.....	160
Eukaryotic Initiation Factor 4E (elf4E).....	161
Prognostic Models.....	161
References.....	162
12 Future Directions.....	167
Collaboration.....	167
Education.....	168
Diagnosis.....	169
Risk Factors.....	169
Vive la Difference.....	170
Neoadjuvant Treatment.....	171
References.....	172